Menarini Group介绍了有关ER+、HER2-转移性乳腺癌的带状复合疗法的有希望的数据。 Menarini Group presents promising data on elacestrant combination therapies for ER+, HER2- metastatic breast cancer.

梅纳里尼集团在ASCO 2025会议上提出了数据,显示ER+,HER2转移性乳腺癌治疗中,使用elacestrant与其他药物结合治疗的结果很有希望. Menarini Group presented data at the ASCO 2025 meeting showing promising results for treating ER+, HER2- metastatic breast cancer with elacestrant combined with other drugs. 该研究 " ELEVATE " 测试了六种治疗组合,早期结果显示,病人使用里皮立布和埃维利穆斯的麻风素获得较好的结果。 The study, ELEVATE, tested six treatment combinations, with early findings indicating better outcomes for patients using elacestrant with ribociclib and everolimus. 这项研究突出了治疗这类乳腺癌的潜在新选择。 This research highlights potential new options for treating this type of breast cancer.